LQDA vs TECX
LQDA: Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension. TECX: A biotechnology company using its proprietary GEODe™ platform to unlock therapeutic protein and antibody treatments for difficult-to-target GPCR-related diseases.
Side-by-side fundamentals
| Metric | LQDA | TECX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $87.04 | $31.59 | |
| Market cap as of 2026-07-23 | $7.7B | $594M | |
| P/E as of 2026-07-23 | 347.02 | n/a | |
| Net margin as of 2026-07-23 | +7.7% | n/a | |
| Gross margin as of 2026-07-23 | +91.8% | n/a | |
| Operating margin as of 2026-07-23 | +15.8% | n/a | |
| ROE as of 2026-07-23 | +46.8% | -32.3% | LQDA higher |
| ROA as of 2026-07-23 | +7.1% | -30.9% | LQDA higher |
| Debt / equity as of 2026-07-23 | 1.64 | 0.00 | TECX lower |
| Revenue growth (YoY) as of 2026-07-23 | +1936.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +115.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.58 | 1.30 | |
| 1-year return as of 2026-07-22 close | +424.3% | +49.6% | LQDA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.